Browse by author
Lookup NU author(s): Professor Anthony MoormanORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Acute lymphoblastic leukaemia (ALL) occurs at all ages but is the most common cancer of childhood. The current treatment of paediatric ALL is highly successful with up to 90% children being cured. In contrast, survival rates for adult ALL are significantly lower at around 40%. The discovery and characterisation of genetic abnormalities have increased our understanding of the biology of the disease and provided important prognostic and predictive markers which have improved patient outcome. Not only is the spectrum of these aberrations vast but, due to advances in technology, continually expanding. A wide range of chromosomal and genomic abnormalities have been reported as being associated with patient outcome but only a subset are currently used to risk stratify patients. This review highlights the main genetic abnormalities which are used to manage patients with B-cell precursor ALL and discusses the evidence which has been accumulated on several newly described genomic abnormalities. (C) 2012 Elsevier Ltd. All rights reserved.
Author(s): Moorman AV
Publication type: Review
Publication status: Published
Journal: Blood Reviews
Print publication date: 19/03/2012
ISSN (print): 0268-960X
ISSN (electronic): 1532-1681
Publisher: CHURCHILL LIVINGSTONE